Advertisement
Research design| Volume 48, ISSUE 6, P615-624, September 15, 2000

Methodological issues in developing new acute treatments for patients with bipolar illness

      Abstract

      One important aim of the recent reorganization of the National Institute of Mental Health (NIMH) is to streamline the development of new treatments for patients with severe mental illnesses, such as bipolar disorder. Researching new treatments for patients with bipolar disorder presents specific problems not readily addressed by traditional efficacy trial methodologies that aim to maximize internal validity. This article reexamines several assumptions that have guided the design of these efficacy trials but that also create obstacles for studies of bipolar disorder and suggests potential solutions. This article draws on literature from neurology and psychiatry and discussions at a MacArthur Foundation–sponsored Conference on Longitudinal Methodology in 1992 (David J. Kupfer, M.D., Chair), which brought together investigators to consider alternative designs for patients with severe and persistent mental illness. In addition, we benefited from discussions at two NIMH-sponsored conferences, one held in 1989 (
      • Prien R.F.
      • Potter W.Z.
      NIMH Workshop report on treatment of bipolar disorder.
      ) and the other in 1994 (
      • Prien R.F.
      • Rush A.J.
      National Institute of Mental Health Workshop report on the treatment of bipolar disorder.
      ), at which investigators and methodologists discussed issues surrounding the development and conduct of informative efficacy trials for patients with bipolar disorder. Based on these discussions and recent literature reviews, we 1) outline common problems in the development and evaluation of effective acute treatments for bipolar disorder and 2) suggest possible solutions to these impediments. We also discuss alternative designs by which to build a sequence of acute treatment studies from which efficacy, safety, and the comparative value of different treatments can be established.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aagaard J.
        • Vestergaard P.
        Predictors of outcome in prophylactic lithium treatment. A two-year prospective study.
        J Affect Disord. 1990; 18: 259-266
      1. American Psychiatric Association Task Force for the Handbook of Psychiatric Measures (2000): Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association.

        • Ballenger J.C.
        • Post R.M.
        Therapeutic effects of carbamazepine in affective illness.
        Commun Psychopharmacol. 1978; 2: 159-175
        • Bauer M.S.
        • Callahan A.M.
        • Jampala C.
        • Petty F.
        • Sajatovic M.
        • Schaefer V.
        • et al.
        Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs.
        J Clin Psychiatry. 1999; 60: 9-21
        • Beck A.T.
        • Rush A.J.
        • Shaw B.F.
        • Emery G.
        Cognitive Therapy of Depression. Guilford, New York1979
        • Beck A.T.
        • Ward C.H.
        • Mendelson M.
        • Mock J.E.
        • Erbaugh J.K.
        An inventory for measuring depression.
        Arch Gen Psychiatry. 1961; 4: 561-571
        • Bowden C.L.
        • Brugger A.M.
        • Swann A.C.
        • Calabrese J.R.
        • Janicek P.G.
        • Petty F.
        • et al.
        Efficacy of divalproax sodium vs. lithium and placebo in the treatment of mania.
        JAMA. 1994; 271: 918-924
      2. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al (2000): A randomized, placebo-controlled 12-month trial of divalproex and lithium treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 57:481–489.

        • Brodie M.J.
        Antiepileptic drugs, clinical trials, and the marketplace.
        Lancet. 1996; 347: 777-779
        • Brodie M.J.
        • Dichter M.A.
        Antiepileptic drugs.
        N Engl J Med. 1996; 334: 168-175
        • Brodie M.J.
        • Richens A.
        • Yuen A.W.
        • UK Lamotrigine/Carbamazepine Monotherapy Trial Group
        Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy.
        Lancet. 1995; 345: 476-479
        • Calabrese J.R.
        • Woyshville M.J.
        Lithium therapy.
        Ann Clin Psychiatry. 1995; 7: 103-112
        • Calabrese J.R.
        • Woyshville M.J.
        A medication algorithm for treatment of bipolar rapid cycling?.
        J Clin Psychiatry. 1995; 56: 11-18
        • Denicoff K.C.
        • Smith-Jackson E.E.
        • Disney E.R.
        • Ali S.O.
        • Leverich G.S.
        • Post R.M.
        Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.
        J Clin Psychiatry. 1997; 58: 470-478
        • Denicoff K.D.
        • Smith-Jackson E.E.
        • Disney E.R.
        • Suddath R.L.
        • Leverich G.S.
        • Post R.M.
        Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p).
        J Psychiatr Res. 1997; 31: 593-603
        • Dennehy E.
        • Suppes T.
        Medication algorithms for bipolar disorder.
        J Pract Psychiatry Behav Health. 1999; 5: 142-152
        • Endicott J.
        • Spitzer R.L.
        • Fleiss J.L.
        • Cohen J.
        The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.
        Arch Gen Psychiatry. 1976; 33: 766-771
        • Fava G.A.
        • Rafanelli C.
        • Grandi S.
        • Canestrari R.
        • Morphy M.A.
        Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression.
        Am J Psychiatry. 1998; 155: 1443-1445
        • Fava G.A.
        • Rafanelli C.
        • Grandi S.
        • Conti S.
        • Belluardo P.
        Prevention of recurrent depression with cognitive behavioral therapy.
        Arch Gen Psychiatry. 1998; 55: 816-820
        • Freeman M.P.
        • Stoll A.L.
        Mood stabilizer combinations.
        Am J Psychiatry. 1998; 155: 12-21
        • George M.S.
        • Huggins T.
        • McDermut W.
        • Parekh P.I.
        • Rubinow D.
        • Post R.M.
        Abnormal facial emotion recognition in depression.
        Behav Modif. 1998; 22: 192-204
      3. Guy W (1976): ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education and Welfare Publication No. 76-338. Washington DC: U.S. Government Printing Office.

        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Hamilton M.
        Development of a rating scale for primary depressive illness.
        Br J Soc Clin Psychol. 1967; 6: 278-296
        • Handforth A.
        • DeGiorgio C.M.
        • Schachter S.C.
        • Uthman B.M.
        • Naritoku D.K.
        • Tecoma E.S.
        • et al.
        Vagus nerve stimulation therapy for partial-onset seizures.
        Neurology. 1998; 51: 48-55
        • Harden C.L.
        • Lazar L.M.
        • Pick L.H.
        • Nikolov B.
        • Goldstein M.A.
        • Carson D.
        • et al.
        A beneficial effect on mood in partial epilepsy patients treated with gabapentin.
        Epilepsia. 1999; 40: 1129-1134
        • Himmelhoch J.M.
        • Garfinkel M.E.
        Sources of lithium resistance in mixed mania.
        Psychopharmacol Bull. 1986; 22: 613-620
        • Judd L.L.
        • Akiskal H.S.
        • Maser J.D.
        • Zeller P.J.
        • Endicott J.
        • Coryell W.
        • et al.
        A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.
        Arch Gen Psychiatry. 1998; 55: 694-700
        • Judd L.L.
        • Akiskal H.S.
        • Paulus M.P.
        The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder.
        J Affect Disord. 1997; 45: 5-17
        • Keck Jr, P.E.
        • McElroy S.L.
        Outcome in the pharmacologic treatment of bipolar disorder.
        J Clin Psychopharmacol. 1996; 16: 15S-23S
        • Keck Jr, P.E.
        • McElroy S.L.
        • Strakowski S.M.
        • Bourne M.L.
        • West S.A.
        Compliance with maintenance treatment in bipolar disorder.
        Psychopharmacol Bull. 1997; 33: 87-91
        • Kessler R.C.
        • McGonagle K.A.
        • Zhao S.
        • Nelson C.B.
        • Hughes M.
        • Eschleman S.
        • et al.
        Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States.
        Arch Gen Psychiatry. 1994; 51: 8-19
        • Kramlinger K.G.
        • Post R.M.
        Ultra-rapid and ultradian cycling in bipolar affective illness.
        Br J Psychiatry. 1996; 168: 314-323
        • Kusalic M.
        • Engelsmann F.
        Predictors of lithium treatment responsiveness in bipolar disorder. A two-year prospective study.
        Neuropsychobiology. 1998; 37: 146-149
        • Leverich G.S.
        • Post R.M.
        Life charting the course of bipolar disorder.
        Curr Rev Mood Disord. 1996; 1: 48-61
        • Leverich G.S.
        • Post R.M.
        Life charting of affective disorders.
        CNS Spectrums. 1998; 3: 21-37
        • Licht R.W.
        • Gouliaev G.
        • Vestergaard P.
        • Frydenbert M.
        Generalisability of results from randomised drug trials. A trial on antimanic treatment.
        Br J Psychiatry. 1997; 170: 264-267
        • Mawer G.E.
        • Jamieson V.
        • Lucas S.B.
        • Wild J.M.
        Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy.
        Epilepsia. 1999; 40: 190-196
        • McDermut W.
        • Pazzaglia P.J.
        • Huggins T.
        • Mikalauskas K.
        • Leverich G.S.
        • Ketter T.A.
        • et al.
        Use of single case analyses in off-on-off-on trials in affective illness.
        Depression. 1995; 2: 259-271
      4. McElroy SL, Altshuler L, Suppes T, Keck PE Jr, Frye MA, Denicoff KD (in press): Axis I psychiatric comorbidity in a cohort of patients with bipolar disorder. Am J Psychiatry.

        • Miller I.W.
        • Keitner G.I.
        • Schatzberg A.F.
        • Klein D.N.
        • Thase M.E.
        • Rush A.J.
        • et al.
        The treatment of chronic depression, part 3.
        J Clin Psychiatry. 1998; 59: 608-619
        • Montgomery S.A.
        • Åsberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Nolen W.A.
        • Knoppert-van der Klein E.A.M.
        • Bouvy P.F.
        • Honig A.
        • Klompenhouwer J.-L.
        • Ravelli D.P.
        Richtlijn Farmacotherapie Bipolaire Stoornissen. Boom, Amsterdam1998
        • Paykel E.S.
        • Scott J.
        • Teasdale J.D.
        • Johnson A.L.
        • Garland A.
        • Moore R.
        • et al.
        Prevention of relapse in residual depression by cognitive therapy.
        Arch Gen Psychiatry. 1999; 56: 829-835
        • Pazzaglia P.J.
        • Post R.M.
        • Ketter T.A.
        • George M.S.
        • Marangell L.B.
        Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation.
        Psychiatry Res. 1993; 49: 257-272
        • Pledger G.W.
        • Sahlroot J.T.
        Alternative analyses for antiepileptic drug trials.
        in: French J.A. Dichter M.A. Leppik I.E. New Antiepileptic Drug Development Preclinical and Clinical Aspects. Epilepsy Research, Supplement 10. Elsevier Science, Amsterdam1993: 167-174
        • Post R.M.
        • Denicoff K.D.
        • Frye M.A.
        • Leverich G.S.
        Algorithms for bipolar mania.
        in: Rush A.J. Mood Disorders. Systematic Medication Management. Modern Problems of Pharmacopsychiatry. Karger, Basel1997: 114-145 (Vol 25.)
        • Post R.M.
        • Frye M.A.
        • Denicoff K.D.
        • Leverich G.S.
        • Kimbrell T.A.
        • Dunn R.T.
        Beyond lithium in the treatment of bipolar illness.
        Neuropsychopharmacology. 1998; 19: 206-219
        • Post R.M.
        • Ketter T.A.
        • Denicoff K.
        • Pazzaglia P.J.
        • Leverich G.S.
        • Marangell L.B.
        • et al.
        The place of anticonvulsant therapy in bipolar illness.
        Psychopharmacology (Berl). 1996; 128: 115-129
      5. Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, George MS, Callahan A, et al (1996): Rational polypharmacy in the bipolar affective disorders. Epilepsy Res (suppl 11):153–180.

      6. Post RM, Leverich GS, Denicoff KD, Frye MA, Kimbrell TA, Dunn R (1997): Alternative approaches to refractory depression in bipolar illness. Depression Anxiety 5:175–189.

        • Post R.M.
        • L’Herrou T.
        • Luckenbaugh D.A.
        • Frye M.A.
        • Leverich G.S.
        • Mikalauskas K.
        Statistical approaches to trial durations in episodic affective illness.
        Psychiatry Res. 1998; 78: 71-87
        • Prien R.F.
        • Potter W.Z.
        NIMH Workshop report on treatment of bipolar disorder.
        Psychopharmacol Bull. 1990; 26: 409-427
        • Prien R.F.
        • Rush A.J.
        National Institute of Mental Health Workshop report on the treatment of bipolar disorder.
        Biol Psychiatry. 1996; 40: 215-220
        • Rush A.J.
        • Giles D.E.
        • Schlesser M.A.
        • Fulton C.L.
        • Weissenburger J.
        • Burns C.
        The Inventory for Depressive Symptomatology (IDS).
        Psychiatry Res. 1986; 18: 65-87
        • Rush A.J.
        • Gullion C.M.
        • Basco M.R.
        • Jarrett R.B.
        • Trivedi M.H.
        The Inventory of Depressive Symptomatology (IDS).
        Psychol Med. 1996; 26: 477-486
        • Sachdeo R.C.
        • Reife R.A.
        • Lim P.
        • Pledger G.
        Topiramate monotherapy for partial onset seizures.
        Epilepsia. 1997; 38: 294-300
        • Sachs G.S.
        Bipolar mood disorder.
        J Clin Psychopharmacol. 1996; 2: 32S-47S
        • Solomon D.A.
        • Keitner G.I.
        • Ryan C.E.
        • Miller I.W.
        Polypharmacy in bipolar I disorder.
        Psychopharmacol Bull. 1996; 32: 579-587
        • Spearing M.K.
        • Post R.M.
        • Leverich G.S.
        • Brandt D.
        • Nolen W.
        Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP).
        Psychiatry Res. 1997; 73: 159-171
        • Strakowski S.M.
        • Sax K.W.
        • McElroy S.L.
        • Keck Jr, P.E.
        • Hawkins J.M.
        • West S.A.
        Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization.
        J Clin Psychiatry. 1998; 59: 465-471
        • Suppes T.
        • Rush Jr, A.J.
        • Kraemer H.C.
        • Webb A.
        Treatment algorithm use to optimize management of symptomatic patients with a history of mania.
        J Clin Psychiatry. 1998; 59: 89-96
        • Swann A.C.
        • Bowden C.L.
        • Calabrese J.R.
        • Dilsaver S.C.
        • Morris D.D.
        Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania.
        Am J Psychiatry. 1999; 156: 1264-1266
      7. University of Pittsburgh, Epidemiology Data Center (2000). STAR∗D: Sequenced Treatment Alternatives to Relieve Depression. Available at: www.edc.gsph.pitt.edu/stard. Accessed May 30, 2000.

      8. University of Pittsburgh, Epidemiology Data Center (2000). STEP-BD: Systematic Treatment Enhancement Program for Bipolar Disorder. Available at: http://www.edc.gsph.pitt.edu/stepbd. Accessed May 30, 2000.

        • Woggon B.
        Treatment of bipolar disorder, depressed phase augmentation/switching strategies.
        in: Rush A.J. Mood Disorders. Systematic Medication Management. Modern Problems of Pharmacopsychiatry. Karger, Basel1997: 78-87 (Vol 25)
        • Young R.C.
        • Biggs J.T.
        • Ziegler V.E.
        • Meyer D.A.
        A rating scale for mania.
        Br J Psychiatry. 1978; 133: 429-435
        • Zung W.K.W.
        A self-rating depression scale.
        Arch Gen Psychiatry. 1965; 12: 63-70